Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) has issued an update.
Sihuan Pharmaceutical Holdings Group Ltd. has signed a cooperation agreement with U.S.-based Abalone Bio to jointly develop a new-generation innovative therapy for weight loss and muscle gain. This collaboration aims to advance research in targeting metabolism-related G protein-coupled receptors (GPCRs) to improve energy expenditure safely and effectively. The partnership leverages Abalone’s proprietary technology and Sihuan’s R&D resources to address current limitations in obesity treatments and enhance the company’s strategic position in the GPCR target field. This agreement marks a significant step in Sihuan’s strategy to deepen its involvement in the GPCR field, following its previous investment in DJS Antibodies.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative therapies. The company is involved in the research and development of drugs, particularly in the field of metabolic diseases, and has a strong presence in the Greater China markets.
Average Trading Volume: 74,884,029
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.62B
See more insights into 0460 stock on TipRanks’ Stock Analysis page.